Table 5 Postoperative complications during hospitalization in the ICU and short-term outcomes of the recipients; donor BMI univariate analysis
|  | Overall, N = 279 (100%) | Donor underweight, N = 10 (3.6%) | Donor normal weight, N = 128 (46%) | Donor overweight, N = 95 (34%) | Donor obesity, N = 46 (16%) | p value |
|---|---|---|---|---|---|---|
At admission in the ICU | ||||||
 SAPS II at admission in ICU, med [IQR] | 44 [39–53] | 40 [36–48] | 45 [39–53] | 44 [39–53] | 45 [41–52] | 0.41 |
 SOFA score at admission in ICU, med [IQR] | 8 [7–10] | 6 [6–9.3] | 8 [7–10] | 8 [7–10] | 7.5 [6–10] | 0.30 |
 Serum lactate > 3 mmol/L | 101 (36) | 3 (30) | 46 (36) | 35 (37) | 17 (37) | 0.99 |
 Serum lactate > 2 mmol/L | 170 (61) | 8 (80) | 77 (60) | 62 (65) | 23 (50) | 0.22 |
 Hemodynamic status during hospitalization in ICU |  |  |  |  |  |  |
 Duration of catecholamine support, med [IQR] | 2 [1–4] | 2 [1–7] | 2 [1–4] | 2 [1–4] | 2 [1–3] | 0.75 |
 Atrial fibrillation, n (%) | 103 (37) | 7 (70) | 39 (31) | 43 (45) | 14 (32) | 0.020 |
 MOF syndrome, n (%) | 94 (34) | 4 (40) | 42 (33) | 36 (38) | 12 (26) | 0.54 |
 Duration of ECMO support | 0 [0–2] | 0 [0–0] | 0 [0–2] | 1 [0–3] | 0 [0–0] | 0.004 |
Respiratory complications | ||||||
 Duration of MV, med [IQR] | 3 [1–19] | 5 [1–24] | 3 [1–17] | 3 [1–18] | 3 [1–20] | 0.98 |
 PGD, n (%) | 147 (53) | 4 (40) | 66 (52) | 55 (58) | 22 (48) | 0.54 |
 Grade 3 PGD, n (%) | 74 (27) | 2 (20) | 36 (28) | 30 (32) | 6 (13) | 0.10 |
 NBA administration, n (%) | 85 (31) | 4 (40) | 36 (29) | 32 (34) | 13 (28) | 0.73 |
 Duration of NBA administrationn, med [IQR] | 3 [1–5] | 5 [4–8] | 3 [1–4] | 3 [1–5] | 2 [1–5] | 0.45 |
 Prone positionning, n (%) | 41 (15) | 3 (30) | 17 (13) | 16 (17) | 5 (11) | 0.37 |
 Reintubation | 50 (22) | 2 (22) | 26 (25) | 11 (15) | 11 (28) | 0.28 |
 Tracheostomy for ventilation weaning, n (%) | 80 (29) | 3 (30) | 38 (30) | 27 (28) | 12 (26) | 0.97 |
Infectious complications | ||||||
 Bacteriemia, n (%) | 44 (16) | 3 (30) | 18 (14) | 17 (18) | 6 (13) | 0.50 |
 Mediastinitis, n (%) | 15 (5.4) | 1 (10) | 6 (4.7) | 5 (5.3) | 3 (6.5) | 0.67 |
 Septic shock | 83 (30) | 2 (20) | 36 (28) | 32 (34) | 13 (29) | 0.76 |
 Number of pneumonia, med [IQR] | 1 [1, 2] | 1 [1–1.75] | 1 [1, 2] | 1 [1, 2] | 1 [1, 2] | 0.86 |
Surgical complications | ||||||
 Surgical thoracic reintervention, n (%) | 54 (19) | 1 (10) | 23 (18) | 22 (23) | 8 (17) | 0.71 |
 Abdominal surgery, n (%) | 29 (10) | 2 (20) | 13 (10) | 11 (12) | 3 (6.5) | 0.50 |
Renal complications | ||||||
 AKI, n (%) | 133 (48) | 4 (40) | 62 (49) | 43 (45) | 24 (52) | 0.84 |
 KDIGO stage, med [IQR] | 1 [0–2] | 0 [0–1] | 1 [0–2] | 1 [0–2] | 1 [0–2] | 0.50 |
 Renal replacement therapy, n(%) | 44 (16) | 0 (0) | 19 (15) | 19 (20) | 6 (13) | 0.39 |
Other complications | ||||||
 Bronchial anastomotic dehiscence, n(%) | 38 (16) | 2 (25) | 17 (15) | 9 (11) | 10 (24) | 0.17 |
 Antibody mediated rejection, n (%) | 75 (27) | 2 (20) | 36 (28) | 27 (29) | 10 (22) | 0.83 |
 Acute cellular rejection, n (%) | 33 (12) | 1 (10) | 17 (13) | 10 (11) | 5 (11) | 0.94 |
Outcome | ||||||
 Duration of ICU stay, med IQR] | 17 [9–32] | 20 [9, 11–32] | 17 [10–35] | 18 [12–28] | 15 [9–31] | 0.77 |
 Death on day-90, n (%) | 49 (18) | 0 (0) | 21 (16) | 20 (21) | 8 (17) | 0.45 |